Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis
Liyen Katrina Kan, Kate Drummond, Martin Hunn, David Williams, Terence J O'Brien, Mastura Monif
BMJ Open Neurology | BMJ PUBLISHING GROUP | Published : 2020
Gliomas are the most common central nervous system malignancies and present with significant morbidity and mortality. Treatment modalities are currently limited to surgical resection, chemotherapy and radiotherapy. Increases in survival rate over the previous decades are negligible, further pinpointing an unmet clinical need in this field. There is a continual struggle with the development of effective glioma diagnostics and therapeutics, largely due to a multitude of factors, including the presence of the blood-brain barrier and significant intertumoural and intratumoural heterogeneity. Importantly, there is a lack of reliable biomarkers for glioma, particularly in aiding tumour subtyping a..View full abstract
This study was funded by Brain Foundation Australia.